|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
The effects of cisplatin include activation of caspases, proteolysis of enzyme poly ADP ribose polymerase (PARP), control of apoptosis modulators B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), and BH3-interacting domain death agonist (Bid), and cell cycle arrest in G2/M phase.
|
30845773 |
2019 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
Importantly, pBD129 elevated the expression level of Bcl-2-associated death promoter (Bcl-2), but down-regulated the expression levels of apoptosis-related genes such as the B-cell lymphoma-2-associated X protein (Bax), BH3-interacting domain death agonist (Bid), cysteinyl aspartate-specific proteinase-3 (Caspase-3), and caspase-9 in the intestinal mucosa (<i>P</i> < 0.05).
|
31636641 |
2019 |
|
B-Cell Lymphomas
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Combination treatment reduced the expression of B-cell lymphoma 2 (BCL2), BH3 interacting domain death agonist (BID), and BCL-x/L.
|
30343279 |
2018 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
Furthermore, the pro‑apoptotic factors Bcl‑2 X‑associated protein and BH3 interacting domain death agonist were uregulated, while the anti‑apoptotic factors B‑cell lymphoma 2 (Bcl‑2) and Bcl‑2‑extra large were downregulated.
|
29363721 |
2018 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
Furthermore, our data revealed that Z-IETD-FMK also blocked increase of truncated BH3 interacting domain death agonist (tBID)/BID, decrease of the B-cell lymphoma 2 (Bcl-2)/Bcl-2 associate X protein (Bax) ratio and mitochondrial membrane potential (MMP), release of cytochrome c, as well as cleavage of caspase-9/3 and poly (ADP-ribose) polymerase (PARP) induced by Cd.
|
29891925 |
2018 |
|
B-Cell Lymphomas
|
0.080 |
AlteredExpression
|
group |
BEFREE |
The results showed that poly (I:C) transfection markedly induced HeLa apoptosis, increased the protein levels of pro‑apoptotic B cell lymphoma‑2 (Bcl‑2)‑associated X protein (Bax) and BH3 interacting‑domain death agonist (Bid), and suppressed the protein expression levels of anti‑apoptotic Bcl‑2 and Survivin.
|
26848042 |
2016 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
These observations were found to correlate with increases in truncated BH3 interacting‑domain death agonist and B‑cell lymphoma 2 (Bcl‑2) interacting mediator of cell death, but not Bcl‑2 homologous antagonist killer, Bcl‑2‑associated X protein, Bcl‑2, B‑cell lymphoma‑extra large and induced myeloid leukemia cell differentiation protein levels.
|
24270523 |
2014 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
Here, we report that elevated oxygen (hyperoxia) triggers a marked increase in active caspase-2 expression, resulting in an initiation of the intrinsic apoptotic pathway with upregulation of key proteins, namely, cytochrome c, apoptosis protease-activating factor-1, and the caspase-independent protein apoptosis-inducing factor, whereas BH3-interacting domain death agonist and the anti-apoptotic protein B-cell lymphoma-2 are downregulated.
|
22237207 |
2012 |